The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Services
  • Sports
  • Financial
  • Books

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
  • Twin Flame Visions Disrupts the Industry With Record Ad Performance and Rapid User Growth
  • SIMM Capital Fund Surpasses $25M Raised and $100M+ in Real Estate Assets
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • Children Rising Appoints Marshelle A. Wilburn as New Executive Director
  • Nonprofit Operations' First-Of-Its-Kind Job Portal Empowers Nonprofit Job Seekers
  • Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
  • Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.

More on The PennZone
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
  • Artificial Intelligence Leader Releases Children's Book on Veterans Day
  • KDG Recognized on the Clutch 1000 List for 2025
  • SNS Research Group has published its flagship report, "Dermatological Drugs Market: 2025–2035"

4930 Bradshaw Court, San Diego, CA  92130
Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business, Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
  • IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
  • Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
  • BPM Systems Launches New Automated Packaging & Labeling Solution for Manufacturers Across The US
  • EnergyStrat Launches Global LNG Risk Outlook 2025–2030
  • Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • Holiday Decorations Most Likely to Cause Injuries
  • UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
  • Zac Arbitman Elected As Co-Chair of Philadelphia Bar Association Federal Courts Committee
  • CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
  • BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
  • UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
  • Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
  • Twin Flame Visions Announces Surge in Traffic and Engagement Following Breakout Ad Performance
  • FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
  • Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California
  • "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide
  • Megan Markovci Honored as One of Top Young Travel Agents in the Industry
  • DanReDev, Kaufman Development & Oldivai Announce Major 2026 Projects Nationwide
  • Twin Flame Visions Disrupts the Industry With Record Ad Performance and Rapid User Growth

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 848
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 259
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 113
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • Cut Costs & Boost Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles
  • Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
  • Discover Elevated Living - Preview the Stunning New Townhome Collection
  • Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
  • Slotozilla's Q3 2025: SBC Lisbon Outcomes and Partnership Expansion
  • New Smile Now Introduces RAYFace 3D Scanner to Advance Digital Surgery

Similar on PennZone

  • NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
  • LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • Artificial Intelligence Leader Releases Children's Book on Veterans Day
  • KDG Recognized on the Clutch 1000 List for 2025
  • Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
  • CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
  • From MelaMed Wellness to Calmly Rooted: A New Chapter in Functional Wellness
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us